Vir Biotechnology Inc. has appointed David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO).

Vir Biotechnology recently announced that it will present Phase 2 SOLSTICE trial data on its elebsiran and tobevibart combination for chronic hepatitis delta at the AASLD Liver Meeting 2026 in Denver, highlighting patterns of HDV RNA response and intrahepatic immune changes through Week 96. The dual focus on antiviral efficacy and natural killer cell remodeling underscores Vir’s attempt to position this investigational regimen as a differentiated, mechanism-rich approach in a...

HC Wainwright lifted their target price on shares of Vir Biotechnology from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday.

Vir Biotechnology will present Week 96 SOLSTICE results on November 8, 2026. Eight analysts support

Vir will present hepatitis delta data on November 8, 2026. Eight analysts give Vir Biotechnology sto

Both are scheduled as oral presentations on Nov. 8 at the American Association for the Study of Liver Diseases meeting in Denver, running Nov. 5-9, 2026.

SAN FRANCISCO, October 05, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026.